肿瘤药学2025，Vol.15Issue(5)：600-608,9.DOI:10.3969/j.issn.2095-1264.2025.05.05
驱动基因阴性晚期非小细胞肺癌一线免疫治疗进展
Advances in first-line immunotherapy for driver gene-negative advanced non-small cell lung cancer
摘要
Abstract
Immunotherapeutic agents represented by immune checkpoint inhibitor(ICI)have demonstrated favorable ef-ficacy in non-small cell lung cancer(NSCLC),changing the treatment strategy for driver gene-negative advanced NSCLC.For advanced NSCLC patients with high PD-L1 expression,ICI monotherapy has been approved as a first-line treatment.Multiple phase Ⅲ clinical trials have confirmed that ICI monotherapy combined with chemotherapy significantly improves patient prognosis in the first-line treatment of driver gene-negative advanced NSCLC.Other combination strategies,such as ICI combined with anti-angiogenic therapy,dual immunotherapy,and immunotherapy combined with antibody-drug con-jugate,have also shown promising efficacy and application potential.Novel immunotherapeutic agents with different targets and mechanisms,as well as various combination regimens,are currently under investigation in clinical trials.These efforts are not only crucial for further improving the clinical outcomes of NSCLC patients but also continuously propelling advance-ments in the field of lung cancer immunotherapy research and development.关键词
非小细胞肺癌/免疫治疗/免疫检查点抑制剂/驱动基因Key words
Non-small cell lung cancer/Immunotherapy/Immune checkpoint inhibitors/Driver gene分类
医药卫生引用本文复制引用
DAI Yunfei,HUANG Yu..驱动基因阴性晚期非小细胞肺癌一线免疫治疗进展[J].肿瘤药学,2025,15(5):600-608,9.基金项目
国家自然科学基金青年项目(82103004) （82103004）
肿瘤精准放射治疗湖北省重点实验室开放基金(2024ZLJZFL001) （2024ZLJZFL001）
华中科技大学同济医学院第一临床学院毕业后教学改革研究项目(XHBJ-2024014). （XHBJ-2024014）
